A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer : Abstrac #5153

Mardjuadi, Feby;Medioni, J.;Kerger, Joseph;Canon, J. L.;Machiels, Jean-Pascal;et.al.
(2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology — Location: (United-States) Orlando, Florida (29.May.2009)

Files

58528.pdf
  • Restricted Access
  • Adobe PDF
  • 380.28 KB
Request a copy

Details

Authors
  • Mardjuadi, FebyUCLouvain
    Author
  • Medioni, J.
    Author
  • Kerger, JosephMGD
    Author
  • Canon, J. L.
    Author
  • Machiels, Jean-PascalUCLouvain
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Mardjuadi, F., Medioni, J., Kerger, J., Canon, J. L., Duck, L., Oudard, S., Clausse, M., D’HONDT, L., Moxhon, A., & Machiels, J.-P. (2009). A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer : Abstrac #5153. Journal of Clinical Oncology, 27(15), 5153. https://hdl.handle.net/2078.5/146684 (Original work published 2009)